BillionToOne study: tissue-free ctDNA assay matches or beats tumor-informed monitoring

BillionToOne reported peer-reviewed real-world study results comparing Northstar Response with a tumor-informed ctDNA monitoring test in advanced cancer. Northstar Response tracked treatment-related disease changes as well as, or better than, the tumor-informed approach. Results support a tissue-free workflow when tumor tissue is unavailable or delays testing.